Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CVL006 + 9MW2821
- Development stage
- Unknown
- Lead developer
- Convalife Pharmaceutical
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
CVL006 + 9MW2821 is an investigational combination therapy being evaluated for the treatment of advanced solid tumors. CVL006 is a bispecific antibody developed by Convalife that dually targets Programmed Death-Ligand 1 (PD-L1) and Vascular Endothelial Growth Factor (VEGF), designed to simultaneously inhibit immune checkpoint evasion and tumor angiogenesis. 9MW2821, developed by Mabwell, is an antibody-drug conjugate (ADC) targeting Nectin-4, which delivers the cytotoxic payload monomethyl auristatin E (MMAE) to tumor cells. The combination is currently in Phase Ib/II clinical development to assess safety, tolerability, and preliminary efficacy in patients with advanced malignancies.
02
Targets
TUBB (Tubulin (alpha and beta subunits))PVRL4 (Nectin cell adhesion molecule 4)VEGFA (Vascular endothelial growth factor A)CD274 (Programmed cell death protein 1 ligand 1)
Beyond the preview
Go deeper on CVL006 + 9MW2821.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CVL006 + 9MW2821.